EGFR and adenocarcinoma in situ: EGFR mutations are significantly associated with the low-grade group (adenocarcinoma in situ [AIS]/minimally invasive adenocarcinoma [MIA]) and the intermediate-group (lepidic/acinar/papillary/invasive mucinous adenocarcinoma) rather than the high-grade group (solid/micropapillary).